Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.69 |
| ▸ | MAOA | P21397 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | CALML3 | P27482 | 1/20 | 0.69 |
| ▸ | SDHA | P31040 | 1/20 | 0.69 |
| ▸ | F10 | P00742 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872739 | 1.00 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL2583967 | 1.00 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL12176864 | 0.89 | MAOB (0.70) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL4150435 | 0.89 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1336215 | 0.88 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL12006775 | 0.88 | MAOB (0.72) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL12126903 | 0.88 | MAOB (0.72) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL15793246 | 0.88 | MAOB (0.72) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL2829207 | 0.88 | MAOB (0.72) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL29439547 | 0.88 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099714-A1 | SYNTHESIS OF DEUTERATED MORPHOLINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-04-09 | — | — | US | disclosed |
| CN-103025730-A | Method for preparing linezolid | UNIV INDIANA RES & TECH CORP | 2013-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099714-A1 | SYNTHESIS OF DEUTERATED MORPHOLINE DERIVATIVES | DRD4, DRD1, DRD2 | MAOB 1448/4885MAOA 2151/4885LMNA 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.